United States Prostate Biopsy Needles Market Supplier, Competition by Manufacturers and Competitor Analysis to 2025


11th JANUARY 2019: The United States Prostate Biopsy Needle Market witnessed a higher CAGR growth in the anticipated period. Prostate biopsy happens when a doctor separates a small sample of tissue from the prostate to detect any cancer. Prostate cancer is very common and common symptoms include difficulty in passing urine, blood in semen or even problems getting or keeping a prolonged erection. Biopsies do not aim at cancer detection in the prostate whereas cancer is detected by non-targeted biopsy schemata. Therefore, the development of novel biopsy devices is currently being investigated or is under development.   
From the commercial viewpoint, prostate biopsy needles enjoy a great deal of attention in the United States due to rising incidences of ultrasound for prostate biopsy. Driving factors responsible for the growth of United States Prostate Biopsy Needle Industry includes rising rate of male population across the world with bladder and prostate problems coupled with sedentary lifestyle. Also, the rise in disposable income and availability of proper medical measures also adds to the growth of United States prostate biopsy needle market. 
Product segmentation for the United States Prostate Biopsy Needle Market includes metal and plastic. Metal segment dominates the market growth in the prescribed period due to lightweight and hygiene. Segmentation for application, the United States Prostate Biopsy Needle Industry includes ambulatory surgical centers, hospitality and specialty clinics. Hospitality and specialty clinics are likely to grow in the near future owing to the rising rate of patient inflow and need for medical diagnosis for male patients.
Geographical segmentation for United States Prostate Biopsy Needle Industry spans Southwest, The West, The Middle Atlantic, The South, The Midwest and New England. The key players in the United States Prostate Biopsy Needle Market include Bard Medical, SRS Medical, CR Bard, Boston Scientific and MDS. 

Comments